Mazdutide anti-obesity drug achieves 11.7% body weight loss at 12-weeksInnovent Biologics has announced that the results of a phase 1b study of mazdutide (IBI362), a glucagon-like peptide-1 (GLP-1) and...
LSG and RYGB-induced upregulation of apoA-IV is beneficial for insulin secretion and energy expenditure2 days ago
Tirzepatide reduced sleep apnoea severity by up to nearly two-thirds in adults living with OSA and obesity2 days ago